QuidelOrtho Corporation (QDEL) fair value analysis
Nasdaq · Updated 2026-10-19
QDEL price how computed
Forward Fair Value verdict
UndervaluedQDEL is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $12.91
- Sector
- Healthcare
- 12-month range
- $9.96–$35.38
- Market cap
- $885M
- From 52-week high
- -63.5%
- Shares outstanding
- 68.6M
- Rank in Healthcare by discount to fair value
- #101 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
QuidelOrtho Corporation is a healthcare company that develops, manufactures, and distributes diagnostic testing solutions, including products for infectious disease, cardiology, and women's health applications. The company operates globally with a presence across multiple continents to serve healthcare providers, laboratories, and patients worldwide.
QDEL currently ranks #101 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $885M
- P/E (trailing)
- 10x
- Revenue (TTM)
- $2.67B
- Net margin
- -39.2%
- EPS (TTM)
- $1.35
- Gross margin
- 43.3%
- Debt / equity
- 1.73
- Revenue growth (3-yr avg)
- -5.1%
- Shares outstanding
- 68.6M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 58 · neutral
- 50-day average
- $12.84
- 200-day average
- $17.18
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+425.0%)
2026-03 ▼ miss (-111.1%)
2025-12 ▲ beat (+9.5%)
2025-09 ▲ beat (+56.9%)
2025-06 ▲ beat (+1100.0%)
2025-03 ▲ beat (+25.4%)
2024-12 ▲ beat (+8.6%)
2024-09 ▲ beat (+165.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 1 hold · 1 sell (3 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $14.7
- Target vs last price
- +13.9%
What our data shows for QDEL
- Our model validated 15 trailing price-to-earnings windows for QDEL, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $9.96–$35.38.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for QDEL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent QDEL news
TickrTrends' derived news-sentiment signal for QDEL is currently leaning positive, computed from recent coverage.
- QuidelOrtho (QDEL) Shares Surge 11.52% Amid Volatile Trading on October 20, 2026 (gurufocus.com, 2026-10-20)
TickrTrends take: QuidelOrtho's significant single-day share movement on October 20, 2026 reflects the type of volatility that can obscure underlying valuation fundamentals in the Healthcare sector. For investors focused on valuation metrics rather than daily price swings, TickrTrends' Undervalued designation suggests the company's intrinsic worth may not be fully reflected in short-term trading activity. When evaluating QDEL alongside its sector peers, valuation-conscious readers should consider whether such volatility presents opportunities to assess the stock against its longer-term fundamental metrics rather than reacting to daily fluctuations.
What people are saying
Follow the QDEL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for QDEL show mixed signals this week. The 50/200-day trend state shifted from downtrend to mixed, while the RSI zone improved from oversold to neutral territory. The stock's sector discount rank moved from number 16 to number 26, indicating a reduced valuation advantage relative to other Healthcare sector companies, though the current valuation verdict remains undervalued.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — QDEL in the Healthcare sector is currently trading at an undervalued valuation verdict. The Relative Strength Index moved from the neutral zone into oversold territory this week, while the stock's sector discount rank improved from 28th to 18th position among Healthcare companies.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is QDEL stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), QDEL is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is QDEL's TickrTrends verdict?
QDEL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does QDEL compare to other Healthcare stocks?
QDEL ranks #101 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is QDEL overbought or oversold?
QDEL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does QDEL report earnings next?
QDEL's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does QDEL usually beat earnings estimates?
Over its last 8 reported quarters QDEL beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about QDEL?
Of 3 analysts covering QDEL, 1 rate it a buy, 1 a hold and 1 a sell - hold-leaning, with a consensus price target of $14.7 (+13.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
QDEL vs EIKN · QDEL vs GEHC · QDEL vs IDXX · QDEL vs INDV · QDEL vs ISRG